OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Google Secures Pentagon AI Deal for Classified Projects 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
BRIDGEWATER, N.J., May 08, 2017 -- Valeritas Holdings, Inc. (NASDAQ:VLRX) announced today that the Company is scheduled to present at the 18th Annual B. Riley Co. Investor Conference.
| Event: | 18th Annual B. Riley Co. Investor Conference |
| Format: | Presentation and One-on-One Meetings |
| Date: | Wednesday, May 24, 2017 |
| Time: | 1:00pm PT |
| Location: | Santa Monica, CA |
An audio webcast of the Company’s presentation will be available by visiting the investor relations section of the Valeritas website at www.valeritas.com. Replays of the presentation will be available for 90 days.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Investor Contacts: Nick Laudico / Robert Flamm, Ph.D. The Ruth Group 646-536-7030 / 7017 [email protected] Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 [email protected] Media Contact: Kirsten Thomas The Ruth Group 508-280-6592 [email protected]
